Lucence Prioritizes Clinical Excellence in Diagnostics

The recent results from Grail’s major multi-cancer early detection (MCED) study have sharpened focus on how multi-cancer early detection tests should be built. Many current tests focus primarily on methylation signals in the blood. However, cancer biology is complex. Tumors release different types of signals, including genetic changes and RNA activity, not just epigenetic methylation. At very early stages of cancer, tumor-derived signals are present at extremely low levels. The defining challenge is distinguishing true cancer signal from background noise with high precision. Lucence’s MCED platform integrates circulating DNA mutation and RNA analysis within a rigorously controlled analytical framework engineered for real-world low-signal detection. As more prospective data becomes available, test differentiation will be defined by validation depth and reproducible performance. Patients deserve tools that can be trusted in real-world clinical care.

🧬 Multiomic Characterization of Small Cell Lung Cancer A large real-world analysis published in Cancer evaluated 944 SCLC tumors using DNA sequencing, RNA sequencing, and immunohistochemistry to better define molecular subtypes and therapeutic targets. Dr. Sonam Puri and colleagues classified tumors by dominant transcription factor expression (ASCL1, NEUROD1, POU2F3, YAP1) and identified meaningful biological differences. The SCLC-Y subtype showed the strongest immune-related gene signatures, suggesting potential relevance for immunotherapy. Subtype-specific targets such as DLL3 and BCL2 (SCLC-A) and SSTR2 (SCLC-N) were also identified. This study reinforces the molecular heterogeneity of SCLC and supports biomarker-driven treatment strategies in a historically uniform disease. https://lnkd.in/ePYXbRcG #SCLC #PrecisionOncology #Immunotherapy #CancerResearch

🔥 #EditorsChoiceArticles 1️⃣ Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer ➡️ Read now: https://brnw.ch/21x0mLM 2️⃣ Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database ➡️ Read now: https://brnw.ch/21x0mLL 3️⃣ Consensus Recommendations to Optimize the Detection and Reporting of NTRK Gene Fusions by RNA-Based Next-Generation Sequencing ➡️ Read now: https://brnw.ch/21x0mLO 4️⃣ Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation ➡️ Read now: https://brnw.ch/21x0mLK 📚 Full Collection: https://brnw.ch/21x0mLN #OncologyResearch #OpenAccess #CallForReading

Long-read sequencing is gaining traction in cancer research and clinical genomics due to its capability to resolve complex genomic variations and access previously unreachable regions of the genome. However, dedicated workflows for comprehensive somatic variant analysis from long-read whole-genome data are still limited, hindering its adoption in cancer genomics. Introducing LRSomatic, a Nextflow-based, nf-core-compliant pipeline designed to support somatic SNV, indel, structural variant, and copy number calling from PacBio HiFi and ONT data. Key features of LRSomatic include: - Support for paired tumor-normal and tumor-only designs - Integration of epigenetic data via Fiber-seq Benchmarked on COLO829 and HG008 reference cell lines, LRSomatic demonstrates state-of-the-art performance across both platforms and variant types. In a case study involving clear cell sarcoma, LRSomatic successfully recovers all identified driver alterations, including the pathognomonic EWSR1::ATF1 fusion, while also resolving haplotype-specific chromatin accessibility through Fiber-seq. Learn more: https://lnkd.in/gPMZbaiv

Early detection can save lives and the right screening plays a crucial role in identifying cancer at a stage when treatment can be most effective. In this feature, Dr. Amrit Kaur Kaler, Consultant - Molecular Pathology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, shares insights on the various methods of cancer screening, the role of genetic testing, and how emerging technologies such as liquid biopsy are shaping early cancer detection. Understanding who should get screened, when genetic testing is recommended, and how to interpret these results can help individuals make informed decisions about their health. Early awareness, accurate screening, and expert guidance are key steps toward better cancer outcomes. [Kokilaben Hospital, Kokilaben Mumbai, Genetic Testing in Oncology, Expert Guidance, Every Life Matters, Early Cancer Detection, Personalised Treatment]

Early detection can save lives and the right screening plays a crucial role in identifying cancer at a stage when treatment can be most effective. In this feature, Dr. Amrit Kaur Kaler, Consultant - Molecular Pathology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, shares insights on the various methods of cancer screening, the role of genetic testing, and how emerging technologies such as liquid biopsy are shaping early cancer detection. Understanding who should get screened, when genetic testing is recommended, and how to interpret these results can help individuals make informed decisions about their health. Early awareness, accurate screening, and expert guidance are key steps toward better cancer outcomes. [Kokilaben Hospital, Kokilaben Mumbai, Genetic Testing in Oncology, Expert Guidance, Every Life Matters, Early Cancer Detection, Personalised Treatment]

Genetic polymorphisms in the TGFB1 signal peptide and promoter region may play a role in Wilms tumor susceptibility. Understanding these genetic variations can help improve early detection and targeted treatment strategies for this childhood cancer. Read full article at : https://lnkd.in/gNtWuFX9 . . . #KidneyCancer #RenalCancer #RenalCellCarcinoma #RCC #KidneyCancerResearch #OncologyResearch #CancerResearch #MedicalResearch #OncologyUpdates #CancerScience #ScientificPublication #JournalPublication #AcademicResearch #PeerReviewed #BiomedicalResearch #ClinicalTrials #TranslationalResearch #OncologyCommunity #UrologicOncology #CancerBiomarkers

Will cancer diagnosis one day be possible with a simple blood test? 🩸🧬 Over the past years, more and more news has been emerging about advances in liquid biopsy technologies and the analysis of circulating tumor DNA (ctDNA). These approaches aim to detect tumor mutations from a blood sample — opening the door to faster and less invasive cancer diagnostics. For clinical laboratories, this could mean several major advantages: ✅ Less invasive procedures for patients ✅ More frequent monitoring of disease progression ✅ Faster identification of actionable mutations In many oncology workflows, this could shift testing from a single tissue biopsy to a more dynamic genetic monitoring of the disease. But it also raises new challenges for labs: 🔬 Analytical sensitivity 💻 Bioinformatics and variant interpretation ⚙️ Integration into existing clinical workflows Molecular diagnostics is no longer just about detecting a mutation. It’s about understanding the genetic evolution of disease in real time. Curious to hear your thoughts 👇 Do you think liquid biopsy will eventually become standard practice in oncology diagnostics, or will it remain complementary to tissue biopsy? #MolecularDiagnostics #LiquidBiopsy #ClinicalGenomics #NGS #PrecisionMedicine

New Post: Joint Variational Graph‑Alignment for Multi‑Omics Integration of Single‑Cell Transcriptomics, Spatial Transcriptomics, and Proteomics to Elucidate Immune Checkpoint Regulation in Colorectal Cancer Metastasis - — ### Abstract The heterogeneity of the tumour micro‑environment \(TME\) is a principal driver of therapeutic resistance in colorectal cancer \(CRC\). While single‑cell RNA sequencing \(scRNA‑seq\) and spatial transcriptomics \(ST\) provide complementary views of cellular identity and spatial relationships, proteomics adds functional read‑outs that are essential for modelling immune checkpoint dynamics. We present **JVGA‑CRC** \(Joint \[…\]

Do you know HER2? HER2 is a biomarker — an important piece of health information that helps patients and healthcare teams better understand a tumor’s biology, how it may behave, and which treatments are most likely to be effective. HER2 is a gene involved in regulating cell growth and survival. While HER2 is widely recognized in breast cancer, it is also relevant across multiple cancer types, including colorectal cancer. HER2 abnormalities occur in approximately 3–5% of colorectal cancers (CRC) and may help inform more personalized treatment strategies. Expanding awareness and access to biomarker testing is essential to ensuring patients receive the most informed care possible. Has HER2 or biomarker testing influenced your clinical practice, research, or advocacy work? #ColorectalCancer #HER2 #KnowYourBiomarker #GCCA